肾功能不全患者经肾清除抗生素减量后能否达到充分药物暴露:系统综述
该系统综述检索Ovid Medline与Embase(至2019年7月),纳入27项报告肾功能不全患者抗生素减量后药物暴露或PK/PD靶值达标情况的研究,多数为β-内酰胺类。仅美罗培南有较好证据,减量者药物暴露为肾功能正常常规剂量者的158%~286%;其余抗生素最多仅一项高质量研究,整体证据不足。
要点
- 肾功能不全时经肾清除抗生素的推荐减量在各指南间不一致,缺乏高质量证据支持。
- 美罗培南减量后暴露反而高于肾功能正常常规剂量者,提示可能减量过度。
- 除美罗培南外,其他经肾清除抗生素减量的充分性缺乏高质量研究证据。
核心结论
- 除美罗培南外,尚无高质量证据支持肾功能不全患者经肾清除抗生素的推荐减量方案。
研究设计与样本
- 系统综述,检索Ovid Medline与Embase自建库至2019年7月,4202项研究中纳入27项。
- 纳入标准为报告肾功能不全患者抗生素减量后药物暴露和/或PK/PD靶值达标的研究。
- 减量充分定义为患者药物暴露或PK/PD参数在肾功能正常常规剂量者的80%~125%范围内,或PK/PD达标率至少90%。
主要发现
- 27项研究中15项质量评为一般,多数研究涉及β-内酰胺类(12/27)。
- 美罗培南证据最佳,纳入4项研究,其中2项质量良好。
- 肾功能不全患者接受美罗培南减量后,药物暴露比肾功能正常接受常规剂量者高158%至286%。
- 其他抗生素最多仅能识别出一项高质量研究。
关键数值与推荐
- 减量充分性判定:药物暴露或PK/PD参数在参考范围80%~125%内,或PK/PD达标率至少90%。
- 美罗培南减量后暴露为肾功能正常常规剂量者的158%~286%。
临床怎么用
- 临床对肾功能不全患者使用美罗培南减量时,应关注暴露可能偏高,结合PK/PD评估个体化给药。
- 其他经肾清除抗生素的减量方案证据有限,不宜简单照搬指南推荐剂量。
局限性
- 多数纳入研究质量仅为一般,高质量研究少。
- 除美罗培南外,其他抗生素缺乏高质量证据,结论外推受限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: There is inconsistency between many guidelines in the recommended dose reduction of renally cleared antibiotics in patients with impaired renal function. OBJECTIVES: This systematic review summarizes the available evidence on the adequacy of the recommended dose reduction in terms of achieving sufficient antibiotic drug exposure or pharmacokinetic/pharmacodynamic target attainment after treatment with these reduced doses. DATA SOURCES: We systematically searched Ovid Medline and Embase from inception (respectively 1946 and 1947) through July 2019. STUDY ELIGIBILITY CRITERIA: All studies reporting antibiotic drug exposure and/or pharmacokinetic/pharmacodynamic (PK/PD) target attainment after dose reduction of antibiotics in patients with impaired renal function. PARTICIPANTS: Adult patients with or without infections. INTERVENTIONS: Administration of reduced doses of antibiotics (orally, intravenously or intramuscularly). METHODS: The reduced dose was considered adequate when the most relevant parameters of drug exposure or PK/PD target attainment in patients with impaired renal function were within a range of 80% to 125% of that patients with adequate renal function receiving a regular dose (reference) or when PK/PD target attainment was attained in at least 90% of the patients with impaired renal function, regardless of the lack of a reference group. RESULTS: Twenty-seven of the 4202 identified studies were included. The quality of 15 of 27 studies was fair, and most studies were of β-lactams (12/27). Best evidence was available for meropenem: four studies were included, of which two studies were of good quality. Drug exposure for meropenem is 158% to 286% higher in patients with impaired renal function receiving reduced doses compared to patients with adequate renal function receiving regular doses. For all other antibiotics, a maximum of one good-quality study could be identified. CONCLUSIONS: No good-quality evidence on the recommended dose reduction of renally cleared antibiotics in patients with impaired renal function is present, with the exception of meropenem.
引用
- de Vroom SL, van Daalen FV, Zieck SE, et al. Does dose reduction of renally cleared antibiotics in patients with impaired renal function lead to adequate drug exposure? A systematic review. Clin Microbiol Infect. 2020. PMID: 33290864. doi:10.1016/j.cmi.2020.11.032
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。